EP 1565452 B1 20120404 - 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS
Title (en)
3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS
Title (de)
3-SUBSTITUIERTE-6-ARYL- PYRIDIN DERIVATE ALS LIGANDEN FÜR C5A-REZEPTOREN
Title (fr)
6-ARYL PYRIDINES SUBSTITUEES EN POSITION 3 EN TANT QUE LIGANDS DES RECEPTEURS C5A
Publication
Application
Priority
- US 0335694 W 20031107
- US 42528102 P 20021108
Abstract (en)
[origin: WO2004043925A2] 3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.
IPC 8 full level
C07D 401/06 (2006.01); A61P 9/00 (2006.01); A61P 29/00 (2006.01); C07D 213/30 (2006.01); C07D 213/38 (2006.01); C07D 213/42 (2006.01); C07D 213/64 (2006.01); C07D 213/65 (2006.01); C07D 213/68 (2006.01); C07D 213/71 (2006.01); C07D 213/74 (2006.01); C07D 213/81 (2006.01); C07D 213/84 (2006.01); C07D 213/89 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07B 61/00 (2006.01)
CPC (source: EP US)
A61P 9/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); C07D 213/30 (2013.01 - EP US); C07D 213/38 (2013.01 - EP US); C07D 213/42 (2013.01 - EP US); C07D 213/64 (2013.01 - EP US); C07D 213/65 (2013.01 - EP US); C07D 213/68 (2013.01 - EP US); C07D 213/71 (2013.01 - EP US); C07D 213/74 (2013.01 - EP US); C07D 213/81 (2013.01 - EP US); C07D 213/84 (2013.01 - EP US); C07D 213/89 (2013.01 - EP US); C07D 401/04 (2013.01 - EP US); C07D 401/06 (2013.01 - EP US); C07D 401/12 (2013.01 - EP US); C07D 405/12 (2013.01 - EP US); C07D 405/14 (2013.01 - EP US); C07D 413/04 (2013.01 - EP US); C07D 413/06 (2013.01 - EP US); C07D 413/12 (2013.01 - EP US); C07D 413/14 (2013.01 - EP US); C07D 417/14 (2013.01 - EP US); C07D 471/04 (2013.01 - EP US); C07B 2200/05 (2013.01 - EP US); C40B 40/00 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2004043925 A2 20040527; WO 2004043925 A3 20040805; AT E552253 T1 20120415; AU 2003291403 A1 20040603; AU 2003291403 A8 20040603; CA 2504941 A1 20040527; CA 2504941 C 20120626; EP 1565452 A2 20050824; EP 1565452 B1 20120404; US 2004158067 A1 20040812; US 2009176980 A1 20090709; US 2011281837 A1 20111117; US 7342115 B2 20080311; US 7863454 B2 20110104
DOCDB simple family (application)
US 0335694 W 20031107; AT 03768799 T 20031107; AU 2003291403 A 20031107; CA 2504941 A 20031107; EP 03768799 A 20031107; US 4103808 A 20080303; US 70436403 A 20031107; US 98366111 A 20110103